First small molecule targeted therapy to mitigate hearing loss in usher syndrome type 3

The first small molecule targeted therapy for progressive hearing loss has been developed in a mouse model of USH3, an USH classified by progressive loss of hearing and vision starting in the first few decades of life along with variable balance disorder.